[Ip-health] Gilead should price remdesivir at $1 a day

Gabriela Arguedas arguedas.gabriela at gmail.com
Mon May 4 12:15:15 PDT 2020

I'm worried about the conflicting evidence regarding remdesivir's
therapeutic effect for SARS-Cov-2 infection. Besides this issue (pricing
and transparency), Gilead should also fully disclose the results of all the
in vitro and clinical trials.

Kind regards from Costa Rica,

Gabriela Arguedas Ramírez
Profesora asociada
Escuela de Filosofía
Centro de Investigación en Estudios de la Mujer
Universidad de Costa Rica

El lun., 4 may. 2020 a las 11:36, Peter Maybarduk (<pmaybarduk at citizen.org>)

> Gilead Should Price Remdesivir at $1 Per Day
> Statement of Peter Maybarduk, Access to Medicines Director, Public Citizen
> For Immediate Release: May 4, 2020; Contact: David Rosen, mailto:
> drosen at citizen.org, (202) 588-7742 Mike Stankiewicz, mailto:
> mstankiewicz at citizen.org, (202) 588-7779
> Note: The Institute for Clinical and Economic Review (ICER) Friday
> announced two pricing models for remdesivir, marketed by Gilead Sciences as
> a treatment for COVID-19. While ICER’s cost effectiveness model suggests a
> price of $4500, the cost recovery model suggests a price of $1 per day.
> Researchers at the University of Liverpool have calculated that $0.93 per
> dose is the cost of manufacturing remdesivir at scale with a reasonable
> profit. The public has contributed at least $60 million to remdesivir’s
> development through federal grants and clinical trials. The U.S. Food and
> Drug Administration issued an emergency use authorization for remdesivir on
> Friday, and the federal government is expected to begin shipping the drug
> across the country this week.
> Remdesivir should be $1 per day. That is more than the cost of
> manufacturing at scale with a reasonable profit to Gilead.
> Gilead initially developed remdesivir as one of several candidate
> treatments for hepatitis C and has made tens of billions off its successful
> hepatitis C drugs. What is relevant now are Gilead’s new costs and the
> public’s many investments in repurposing remdesivir as a treatment for
> COVID-19.
> If Gilead intends to price remdesivir at more than $1 per day, Gilead must
> fully disclose its research and development costs and all public
> contributions associated with remdesivir’s development. Then payers and
> independent experts can analyze again what constitutes fair pricing in a
> pandemic.
> Gilead should commit its patents and know-how to the public domain so that
> researchers around the world can help bring manufacturing to scale.
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

More information about the Ip-health mailing list